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I Introduction
‘Synthetic cannabinoids’ or, more correctly, 
synthetic cannabinoid receptor agonists 
(SCRAs), are synthetic chemicals that mimic 
the effects of the natural psychoactive 
substances found in cannabis. ‘Legal high’ 
products containing SCRAs have been sold as 
herbal smoking mixtures since at least 2006. 
Recently, new products containing SCRAs have 
emerged such as a ‘resin’ resembling cannabis 
resin and liquids suitable for use in electronic 
cigarettes. The products have been marketed in 
innovative ways and may be sold openly on the 
internet and in specialist ‘smoke’ shops. 
The number of distinct SCRA compounds 
detected through the EU Early Warning  
System (EWS), which monitors the emergence 
of new psychoactive substances in Europe, 
continues to grow, with a total of 134 having 
been notified to the EMCDDA between 2008 
and 2014 (Figure 1).
Their chemical diversity and the rate of 
emergence, makes the detection and 
monitoring of this group of compounds 
particularly challenging, especially in terms of 
the harms associated with their use. 
I Conclusions
The EWS plays a key role in the information 
exchange and continuous monitoring of new 
psychoactive substances in Europe. The synthetic 
cannabinoid receptor agonists are the largest group 
monitored, and they pose particular challenges 
as their detection in body fluids is not routinely 
performed. From our current understanding of 
adverse events, based on monitoring a wide range 
of data sources, it is clear that these substances 
carry the potential to cause harm to human health, 
although the mechanisms of how this happens are 
poorly understood.
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 Manufacture, production   I and distribution
China is the main source country for SCRAs, 
which are shipped as bulk powder to Europe and 
other destinations using established, legitimate 
transport and distribution networks. The purity of 
the substances is rarely reported, but one study 
from South Korea reported purities of between 
75 % and 90 % for bulk powder samples. In 2013, 
more than 21 000 seizures of SCRAs were reported 
to the EWS, amounting to more than 1.5 tonnes 
of material, of which almost 600 kilograms was 
bulk powder. 
The consumer products are assembled in Europe 
for local sale or export. Herbs such as damiana 
(Turnera diffusa) are used as a base, into which 
the active synthetic chemicals are crudely mixed, 
using solvents to dissolve the chemicals first. Once 
mixed, the herbs are dried and packaged for sale 
in units typically containing 1–3.5 grams of herbal 
substance and a small quantity of the active SCRA.
I Hazards and harms
The adverse effects of SCRA products (Figure 2) 
may be linked to both the properties of the 
chemicals and the way the products are produced. 
The high potency of some SCRAs means that 
the potential for toxic effects can be substantial. 
This is compounded by the potential for uneven 
distribution of the active compound, leading 
to some samples containing higher doses. The 
pharmacology and toxicology of SCRAs is not well 
understood, and it is difficult to monitor the harms 
related to individual substances due to the absence 
of analytical confirmation in many cases. However, 
several outbreaks of serious acute intoxications 
involving SCRAs have been reported.
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FIGURE 1 | Synthetic cannabinoids and other new psychoactive 
substances reported to the EWS: cumulative yearly totals 
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FIGURE 2 | Adverse effects associated with SCRA products 
Credit: Wikimedia Commons (left); Finnish National Bureau of Investigation, Forensic laboratory 
(middle); TICTAC Communications Ltd (right).
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During 2013, five deaths associated with the use 
of 5F-PB-22 were reported in the United States. 
In 2014, an outbreak of intoxications was linked to 
ADB-PINACA in Colorado. Towards the end of 2014, 
the media in Russia reported two large outbreaks 
of serious adverse events which were linked to the 
smoking of a ‘legal designer drug’ or ‘spice’, most 
probably containing an SCRA.
In Europe, reports are limited, but the EMCDDA has 
issued public health-related alerts after receiving 
analytically confirmed reports of four deaths and 
13 non-fatal intoxications associated with the use 
of an SCRA called MDMB-CHMICA. 
